Australia's first national biotech incubator established
27 August, 2021Australia's first national biotech incubator is to be established with $40 million funding from the federal government's Medical Research Future Fund.
Inhibitor drug 'primes' the body for anticancer immunotherapy
25 August, 2021Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe and may benefit some patients with advanced cancers.
Smart nanoparticles fight fungal infections
19 August, 2021Newly engineered nanoparticles have demonstrated a remarkable ability to battle one of the most invasive and notoriously resistant fungal infections.
Radio waves improve survival in liver cancer patients
17 August, 2021A targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.
Tiny gel drops culture cells for regenerative medicine
16 August, 2021Micrometre-sized gel drops can provide the extracellular architecture needed for cells to grow and proliferate.
Licence agreement for nasal spray drug delivery platform
13 August, 2021A nasal spray technology that enables the delivery of psychedelic and non-psychedelic drugs to treat mental health disorders will enter development for clinical use.
TGA approves Moderna vaccine in Aus adults
10 August, 2021The TGA has granted provisional approval to Moderna Australia for its COVID-19 vaccine, Spikevax (elasomeran).
Restorative hydrogel offers hope for Parkinson's patients
06 August, 2021The new material is made from natural amino acids and acts as a gateway to facilitate the safe transfer of stem cells into the brain and restore damaged tissue.
COVID-19 nasal spray trial seeks participants in Sydney
21 July, 2021ENA Respiratory has initiated a Phase I human safety study in Sydney for its first-in-class nasal spray for the prevention of COVID-19.
Tetanus neurotoxin could treat depression, Parkinson's, ALS
19 July, 2021A non-toxic derivative of the tetanus neurotoxin (Hc-TeTx) may serve to treat depression and neurodegenerative diseases, as demonstrated in animal models.
Treatment found to reverse dementia in mice
05 July, 2021The SAK3 molecule appeared to help improve memory and learning in a mouse model of Alzheimer's disease.
Edible cholera vaccine candidate made of powdered rice
01 July, 2021A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice.
COVID-19 DNA vaccine trial commences Down Under
29 June, 2021Researchers are set to commence the first Phase 1 human trial of a COVID-19 gene-based DNA vaccine in Australia, delivered via a needle-free system.
Monash to manufacture mRNA COVID-19 vaccine for Phase 1 trials
22 June, 2021Monash University has received $5 million from the Victorian Government to manufacture the first Australian batch of a COVID-19 mRNA vaccine for clinical trials.
Novavax's Phase 3 vaccine trial yields promising results
17 June, 2021Novavax's COVID-19 vaccine demonstrated 100% protection against moderate and severe disease, with 90.4% efficacy overall, in the PREVENT-19 Phase 3 trial.
